#News for #investors and #media: At the AASLD Liver Meeting 2025 (#TLM25), we’ll share new data from our advancing liver disease pipeline - with 21 abstracts covering chronic hepatitis B (CHB), metabolic dysfunction-associated steatohepatitis (MASH), alcohol-associated liver disease (ALD), and primary biliary cholangitis (PBC). We’re committed to addressing the global burden of liver disease through scientific innovation and collaboration. Learn more: https://gsk.to/43lbg0p
About us
We are uniting science, technology and talent to get ahead of disease together. Our community guidelines: https://gsk.to/socialmedia
- Website
-
http://www.gsk.com
External link for GSK
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- London, England
- Type
- Public Company
- Specialties
- Pharmaceutical products and Vaccines
Locations
Employees at GSK
Updates
-
This #RSVAwarenessWeek, we are highlighting the potential impact of RSV on adults aged 50 and over with certain underlying health conditions. Respiratory syncytial virus (RSV) may pose a significant health risk, particularly for older adults and those with certain underlying health conditions. Education can help protect the most vulnerable populations from this virus. Our new global survey reveals a notable underestimation of RSV's severity amongst at-risk adults. Join us in advancing global understanding of RSV by exploring and sharing the latest survey insights. Together, we can make a difference! #AheadTogether #RSVAwarenessWeek
-
“One person doesn’t make a difference. We all come together, and we make it happen.” From facing cancer to co-founding the Multiple Myeloma Research Foundation - MMRF, Kathy Giusti has made a huge difference to the lives of so many living with cancer. Speaking with Emma Walmsley earlier this year, Kathy highlights the power of partnership in giving patients the chance to experience some of life’s most precious moments – like watching her daughter get married. 📽️ Watch the full episode now: https://gsk.to/4hn0gFL
-
Watch our CEO, Emma Walmsley, as she shares her reflections on our Q3 2025 performance ⤵️ More information for investors and media: https://gsk.com #Q3Results #Earnings
Today I’m pleased to report another strong set of GSK results, supporting upgraded guidance for 2025 and positioning us well for 2026 and our longer-term growth outlooks. Our momentum continues with sales growth in all areas and significant R&D progress, including four FDA approvals this year. This is my last quarter to report as CEO, and I want to thank the extraordinary GSK teams for all they've achieved together over the past 9 years – delivering a step-change in operating performance, new prospects for growth and a clear pathway for scale patient impact and sustained shareholder value. So today GSK is a very different company in performance, pipeline and prospects. I'm delighted to be passing the baton to Luke in the new year and cheering everyone at GSK to further success as they combine science, tech and their talent to get ahead of disease together.
-
Today we announce our Q3 2025 results, with another quarter of strong performance and upgraded guidance for 2025. Take a look at the highlights 👇 More insights and information for media and investors: https://gsk.to/4nyuMOn #Q3Results #Earnings
-
#News for #investors and #media: Today we announced an agreement with Empirico to add to our pipeline in COPD and potentially other inflammatory respiratory diseases. Find out more: https://gsk.to/49kXgrd
-
#News for #Investors and #Media: Today we announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to an investigational antibody-drug conjugate in our oncology pipeline. Learn more here: https://gsk.to/3WXipjM
-
#News for #investors and #media: Today we announced an agreement with Syndivia to add to our growing oncology pipeline in prostate cancer. Find out more: https://gsk.to/4nmsS36
-
We are thrilled to be named a Science Magazine Top Employer for the 7th year running! Our commitment to uniting science, technology, and talent drives us to get ahead of disease, together. See what makes GSK a great place to work and how our people are making a difference for patients around the globe. Find out more here: https://gsk.to/43u5qd7 #AheadTogether #GSKProud #SCTopEmployers
-
We’re proud to present our latest research across lupus at this year’s American College of Rheumatology (ACR) Convergence in Chicago. We’re committed to advancing the understanding and treatment of rheumatologic diseases like lupus nephritis (LN) and systemic lupus erythematosus (SLE) and look forward to engaging with the scientific community at #ACR over the next week. Read Isha’s story https://gsk.to/4osDgXZ #Lupus